CompletedNCT01670019
Asenapine or Placebo Added to Antidepressants for Depression
About this title
Read the official source — NCT01670019Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Augusta and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 46
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01670019
- Official title
Show the full official title
A Randomized, Blinded, Comparison of Asenapine and Placebo as Adjunctive Treatment in Patients With Non-Psychotic Major Depressive Disorder Incompletely Responsive to Antidepressant Monotherapy
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Augusta · Durham · Greenville
1 more locations
- Raleigh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Did this study involve medication?
Yes. The study involved medication, including Asenapine 5-20 mg daily and Placebo 1-4 tablets daily.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
